Cargando…
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
Treatments of metastatic melanoma underwent an impressive development over the past few years, with the emergence of small molecule inhibitors targeting mutated proteins, such as BRAF, NRAS, or cKIT. However, since a significant proportion of patients acquire resistance to these therapies, new strat...
Autores principales: | Soumoy, Laura, Schepkens, Corentin, Krayem, Mohammad, Najem, Ahmad, Tagliatti, Vanessa, Ghanem, Ghanem E., Saussez, Sven, Colet, Jean-Marie, Journe, Fabrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280989/ https://www.ncbi.nlm.nih.gov/pubmed/32455924 http://dx.doi.org/10.3390/cancers12051323 |
Ejemplares similares
-
Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms
por: Soumoy, Laura, et al.
Publicado: (2020) -
Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma
por: Soumoy, Laura, et al.
Publicado: (2019) -
Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma
por: Najem, Ahmad, et al.
Publicado: (2022) -
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
por: Krayem, Mohammad, et al.
Publicado: (2018) -
PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)